Skip to main content

Adaptive, Amgen collaborate on development of COVID-19 treatment

The drug will rely on Seattle-based Adaptive’s immune medicine platform to identify antibodies that neutralize the virus using samples taken from patients who have already recovered from COVID-19.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.